Clicky

UCB SA(UCB)

Description: UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.


Keywords: Medicine Biopharmaceutical Organ Systems Autoimmune Disease Alzheimer's Disease Parkinson's Disease Rheumatoid Arthritis Arthritis Psoriasis Osteoporosis Epilepsy Crohn's Disease Rheumatology Allergies Psoriatic Arthritis Immunosuppressants Systemic Lupus Erythematosus Plaque Psoriasis Myasthenia Gravis Ankylosing Spondylitis Immune Thrombocytopenia Hidradenitis Suppurativa Treatment Of Osteoporosis Chronic Inflammatory Demyelinating Polyneuropathy Immunology Diseases Restless Legs Syndrome Certolizumab Pegol Cimzia Keppra Neupro Vimpat Alprazolam Contract Manufacturing Activities Immune Mediated Necrotizing Myopathy Inflammatory Tnf Mediated Diseases Ucb Xyzal Zyrtec

Home Page: www.ucb.com

Allée de la Recherche, 60
Brussels, 1070
Belgium
Phone: 32 2 559 99 99


Officers

Name Title
Mr. Jean-Christophe Tellier CEO & Exec. Director
Ms. Sandrine Dufour CFA Exec. VP & CFO
Ms. Kirsten Lund-Jurgensen Exec. VP of Supply & Technology Solutions
Dr. Dhavalkumar D. Patel M.D., Ph.D. Exec. VP & Chief Scientific Officer
Mr. William J. Silbey Exec. VP & Gen. Counsel
Mr. Jean-Luc Fleurial Exec. VP & Chief HR Officer
Prof. Iris Low-Friedrich Exec. VP, Chief Medical Officer and Head of Devel. & Medical Patient Value Practices
Mr. Emmanuel Caeymaex Exec. VP of Immunology Solutions & Head of US
Mr. Charl van Zyl Exec. VP of Neurology Solutions & Head of EU/International
Ms. Caroline Vancoillie Chief Accounting Officer & CFO of Patient Value Functions

Exchange: BR

Country: BE

Currency: Euro (€)

Forward PE: 17.4825
Trailing PE: 17.0766
Price-to-Book MRQ: 1.5457
Price-to-Sales TTM: 2.3902
IPO Date:
Fiscal Year End: December
Full Time Employees: 8600
Back to stocks